Home » GE TRIALS FIRST PET IMAGING AGENT TO TRACK BLOOD VESSEL GROWTH IN CANCER
GE TRIALS FIRST PET IMAGING AGENT TO TRACK BLOOD VESSEL GROWTH IN CANCER
GE Healthcare, a division of the General Electric Company has begun a clinical study of a new chemical for use in positron emission tomography (PET) imaging that could be used to monitor angiogenesis, the formation of new blood vessels in tumours.
Medical Technology Business Europe (http://mtbeurope.info/news/2006/606014.htm)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May